ArticleOncotarget2014

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.

Jorge Franco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.